Drugs have been associated with the development of thrombocytopenia, thrombotic thrombocytopenia purpura–haemolytic–uraemic syndrome, haemolytic anaemia, and agranulocytosis caused by direct dose-related toxicity and by immune-mediated mechanisms. This article will review the drugs associated with these blood dyscrasias, describe the presumptive mechanisms, and discuss treatment options.
No takes yet. Share an insight, caveat, or question.
Medina et al. (2001) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: